# R2D2 (NCT03845270)

> Her2-positive Lung Cancer Treated With Dedicated Drug

No report yet. It can be ordered.

- Drugs tested: trastuzumab plus pertuzumab plus docetaxel
- Indication: advanced non-small cell lung cancer harboring HER2 mutations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03845270
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Intergroupe Francophone de Cancerologie Thoracique
- Conditions: Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III; HER2 Gene Mutation
- Interventions: pertuzumab + trastuzumab + docetaxel
- Enrollment: 46
- Primary outcome: Overall Response

## Indexed commentary on R2D2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=r2d2-nct03845270